Moxifloxacin injection

Drug Profile

Moxifloxacin injection

Latest Information Update: 14 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fresenius Kabi
  • Class Antibacterials; Azabicyclo compounds; Cyclopropanes; Fluoroquinolones; Piperidines; Pyrrolidines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia; Intra-abdominal infections; Skin and soft tissue infections

Most Recent Events

  • 14 Sep 2015 Launched for Acute exacerbations of chronic bronchitis in USA (IV)
  • 14 Sep 2015 Launched for Acute sinusitis in USA (IV)
  • 14 Sep 2015 Launched for Community-acquired pneumonia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top